Dyne Therapeutics (DYN) Non-Current Deffered Revenue (2019 - 2020)
Dyne Therapeutics (DYN) recorded quarterly Non-Current Deffered Revenue of $13000.0 in Q3 2020, down 69.05% quarter-over-quarter from $42000.0 in Q4 2019.
Dyne Therapeutics (DYN) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Dyne Therapeutics' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $13000.0 for Q3 2020.
- In Q3 2020, Non-Current Deffered Revenue changed N/A year-over-year to $13000.0; the TTM figure through Sep 2020 stood at $13000.0 (changed N/A YoY), while the FY2019 annual figure was $42000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $13000.0 for Q3 2020 at Dyne Therapeutics, down from $42000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $42000.0 in Q4 2019 to a low of $13000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 13,000.00 |
| Dec 31, 2019 | 42,000.00 |